A promising experimental vaccine designed to combat enterotoxigenic Escherichia coli (ETEC), a common cause of diarrheal illness, has been licensed to the biotechnology company Valneva. The vaccine technology is the result of decades of research conducted at the University of Bergen.
ETEC is a significant pathogen responsible for a substantial portion of traveler's diarrhea and can cause severe intestinal distress. The development of a vaccine against this bacterium has been a long-standing goal in public health research.
The licensing agreement with Valneva marks a critical step in potentially bringing this new preventative measure to market. Valneva, known for its work in infectious disease vaccines, is expected to advance the vaccine through further development and regulatory processes.